A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease
Latest Information Update: 01 Jun 2025
At a glance
- Drugs AZD 7798 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms AMALTHEA
- Sponsors AstraZeneca
Most Recent Events
- 13 Jun 2024 New trial record